Uni-Bio Science Group Management
Management criteria checks 4/4
Uni-Bio Science Group's CEO is Frank Zhao, appointed in Apr 2019, has a tenure of 5.67 years. total yearly compensation is HK$900.00K, comprised of 67.1% salary and 32.9% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth HK$499.42K. The average tenure of the management team and the board of directors is 4.3 years and 7.5 years respectively.
Key information
Frank Zhao
Chief executive officer
HK$900.0k
Total compensation
| CEO salary percentage | 67.1% |
| CEO tenure | 5.7yrs |
| CEO ownership | 0.1% |
| Management average tenure | 4.3yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
Is Uni-Bio Science Group (HKG:690) Using Too Much Debt?
Dec 11
Uni-Bio Science Group Limited (HKG:690) Surges 35% Yet Its Low P/E Is No Reason For Excitement
Sep 13Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 26% Dive
Jul 29Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 27% Dive
May 27Is Uni-Bio Science Group (HKG:690) Using Too Much Debt?
Apr 24Uni-Bio Science Group Limited (HKG:690) Held Back By Insufficient Growth Even After Shares Climb 28%
Jan 22Uni-Bio Science Group Limited's (HKG:690) Low P/S No Reason For Excitement
Oct 24Robust Earnings May Not Tell The Whole Story For Uni-Bio Science Group (HKG:690)
Apr 30We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow
Nov 22Estimating The Fair Value Of Uni-Bio Science Group Limited (HKG:690)
Jan 05Companies Like Uni-Bio Science Group (HKG:690) Can Afford To Invest In Growth
Mar 01Uni-Bio Science Group (HKG:690) Share Prices Have Dropped 26% In The Last Five Years
Jan 05
We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow
Nov 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | HK$99m |
| Mar 31 2024 | n/a | n/a | HK$85m |
| Dec 31 2023 | HK$900k | HK$604k | HK$71m |
| Sep 30 2023 | n/a | n/a | HK$67m |
| Jun 30 2023 | n/a | n/a | HK$63m |
| Mar 31 2023 | n/a | n/a | HK$51m |
| Dec 31 2022 | HK$1m | HK$1m | HK$39m |
| Sep 30 2022 | n/a | n/a | HK$16m |
| Jun 30 2022 | n/a | n/a | -HK$7m |
| Mar 31 2022 | n/a | n/a | -HK$13m |
| Dec 31 2021 | HK$2m | HK$907k | -HK$20m |
| Sep 30 2021 | n/a | n/a | -HK$39m |
| Jun 30 2021 | n/a | n/a | -HK$58m |
| Mar 31 2021 | n/a | n/a | -HK$65m |
| Dec 31 2020 | HK$3m | HK$886k | -HK$71m |
| Sep 30 2020 | n/a | n/a | -HK$63m |
| Jun 30 2020 | n/a | n/a | -HK$54m |
| Mar 31 2020 | n/a | n/a | -HK$26m |
| Dec 31 2019 | HK$3m | HK$600k | HK$2m |
| Sep 30 2019 | n/a | n/a | -HK$14m |
| Jun 30 2019 | n/a | n/a | -HK$30m |
| Mar 31 2019 | n/a | n/a | -HK$85m |
| Dec 31 2018 | HK$227k | n/a | -HK$139m |
| Sep 30 2018 | n/a | n/a | -HK$224m |
| Jun 30 2018 | n/a | n/a | -HK$309m |
| Mar 31 2018 | n/a | n/a | -HK$294m |
| Dec 31 2017 | HK$360k | n/a | -HK$279m |
Compensation vs Market: Frank's total compensation ($USD115.80K) is below average for companies of similar size in the Hong Kong market ($USD231.19K).
Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.
CEO
Frank Zhao (59 yo)
5.7yrs
Tenure
HK$900,000
Compensation
Mr. Zhi Gang Zhao, also known as Frank, CPA, MSc, has been the Chief Executive Officer and Executive Director of Uni-Bio Science Group Limited since April 8, 2019. He has been the Chief Financial Officer a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 10.8yrs | HK$1.60m | 27.65% HK$ 102.4m | |
| CEO & Executive Director | 5.7yrs | HK$900.00k | 0.13% HK$ 499.4k | |
| Executive Vice Chairman of the Board | 7.9yrs | HK$284.00k | 2.87% HK$ 10.6m | |
| Financial Controller | 2.8yrs | no data | no data | |
| Head of HR & Administration Department | no data | no data | no data | |
| Head of Marketing & Sales | 4.3yrs | no data | no data | |
| Head of Manufacture Department | no data | no data | 2.19% HK$ 8.1m | |
| Head of Medicine & Registration Department | no data | no data | no data | |
| Head of R&D Department | no data | no data | no data | |
| Company Secretary | 2.8yrs | no data | no data |
4.3yrs
Average Tenure
43.5yo
Average Age
Experienced Management: 690's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 10.8yrs | HK$1.60m | 27.65% HK$ 102.4m | |
| CEO & Executive Director | 10.7yrs | HK$900.00k | 0.13% HK$ 499.4k | |
| Executive Vice Chairman of the Board | 7.9yrs | HK$284.00k | 2.87% HK$ 10.6m | |
| Independent Non-Executive Director | 5.7yrs | HK$120.00k | no data | |
| Independent Non-Executive Director | 8.7yrs | HK$120.00k | no data | |
| Independent Non-Executive Director | 7.1yrs | HK$120.00k | no data | |
| Non-Executive Director | 5.7yrs | HK$120.00k | 1.69% HK$ 6.2m | |
| Non-Executive Director | less than a year | no data | no data |
7.5yrs
Average Tenure
54yo
Average Age
Experienced Board: 690's board of directors are considered experienced (7.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 09:15 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Uni-Bio Science Group Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|